Amgen Inc. (AMGN)
undefined
undefined%
At close: undefined
261.22
0.02%
After-hours Jan 03, 2025, 04:38 PM EST

Company Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA.

Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.

It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer.

It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc.

Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.
Amgen Inc. logo
Country United States
IPO Date Jun 17, 1983
Industry Drug Manufacturers - General
Sector Healthcare
Employees 26,700
CEO Robert A. Bradway

Contact Details

Address:
One Amgen Center Drive
Thousand Oaks, California
United States
Website https://www.amgen.com

Stock Details

Ticker Symbol AMGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000318154
CUSIP Number 031162100
ISIN Number US0311621009
Employer ID 95-3540776
SIC Code 2836

Key Executives

Name Position
Robert A. Bradway Chairman, Chief Executive Officer & President
Dr. David M. Reese M.D. Executive Vice President & Chief Technology Officer
Peter H. Griffith Executive Vice President & Chief Financial Officer
Scott Skellenger Senior Vice President & Chief Information Officer
Dr. Howard Y. Chang M.D., Ph.D. Senior Vice President of Global Research & Chief Scientific Officer
Esteban Santos Executive Vice President of Operations
Jonathan P. Graham J.D. Executive Vice President, General Counsel & Secretary
Justin G. Claeys Vice President of Investor Relations
Matthew C. Busch Chief Accounting Officer & Vice President of Finance
Murdo Gordon Executive Vice President of Global Commercial Operations

Latest SEC Filings

Date Type Title
Dec 06, 2024 4 Filing
Dec 03, 2024 4 Filing
Nov 06, 2024 4 Filing
Nov 06, 2024 4 Filing
Nov 06, 2024 4 Filing
Nov 06, 2024 4 Filing
Nov 06, 2024 4 Filing
Oct 31, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Aug 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...